remove_red_eye 697 Views
#Infectious Diseases #Pharmacist #Public Health #Pulmonary Medicine
Independent experts of an FDA advisory panel voted in favor of the not-for-profit TB Alliances treatment for drug resistant tuberculosis, as a part of a three-drug combination regimen.
The panel on Tuesday voted 14-4 when asked to assess the treatment, pretomanid, in combination with Johnson & Johnsons bedaquiline and linezolid for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). (ET Healthworld, June 7, 2019)